[1]周晓鹰,王晶晶,储奕.肥大细胞、嗜碱细胞与药物过敏及过敏性休克的诊断标志物[J].常州大学学报(自然科学版),2017,(03):69-76.[doi:10.3969/j.issn.2095-0411.2017.03.010]
　ZHOU Xiaoying,WANG Jingjing,CHU Yi.Mast Cell and Basophil, Diagnostic Biomarkers for Drug Allergy and Anaphylaxis[J].Journal of Changzhou University(Natural Science Edition),2017,(03):69-76.[doi:10.3969/j.issn.2095-0411.2017.03.010]
点击复制

肥大细胞、嗜碱细胞与药物过敏及过敏性休克的诊断标志物()
分享到：

常州大学学报(自然科学版)[ISSN:2095-0411/CN:32-1822/N]

卷:
期数:
2017年03期
页码:
69-76
栏目:
生物医学工程
出版日期:
2017-05-28

文章信息/Info

Title:
Mast Cell and Basophil, Diagnostic Biomarkers for Drug Allergy and Anaphylaxis
作者:
周晓鹰1; 2; 王晶晶2; 储奕2
1.英国南安普顿大学 医学院,南安普顿SO16 6YD; 2.常州大学 制药工程与生命科学学院,江苏 常州 213164
Author(s):
ZHOU Xiaoying1; 2;  WANG Jingjing2;  CHU Yi2
1.The School of Medicine, University of Southampton, Southampton SO16 6YD, UK; 2.School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou 213164, China
关键词:
药物过敏;  过敏性休克;  肥大细胞;  嗜碱细胞;  诊断标志物
Keywords:
allergy;  anaphylaxis;  mast cells;  basophils;  diagnostic biomarkers
分类号:
R 392.8
DOI:
10.3969/j.issn.2095-0411.2017.03.010
文献标志码:
A
摘要:
药物过敏及其导致的过敏性休克对医患双方都是很严重问题,过敏的发生不可预测,且可危及生命。随着全世界新药新化合物的不断出现,药物过敏问题变得越来越常见和突出。目前药物过敏的诊断方法主要是皮试、皮内点刺、皮肤斑贴、激发试验和血液特异性IgE水平,但这些方法都有一定的限制,而皮试等体内试验本身就具有极大的风险,所以研究诊断生物标志物以及建立体外诊断方法和过敏预测系统则尤其必要。肥大细胞和嗜碱细胞是过敏反应的核心细胞,其激活释放化学介质是这些细胞的主要特征。近10年来,对于药物过敏及过敏性休克发生的细胞激活机制、细胞特异性介质的特征以及作为诊断标志物的研究有了很大的进展,其中包括肥大细胞特异性蛋白酶:类胰蛋白酶、类糜蛋白酶、羧肽酶; 嗜碱细胞活化的细胞表面标志物CD63、CD203C和特异性的basogranulin; 还有其他和过敏症状相关的体内化学介质,如组胺、二肽肽酶Ⅰ、血管紧张素转化酶和缓激肽等。由于过敏反应是一个复杂的快速的病理反应,其诊断需要多重复合标志物的协同使用,所以荧光染料、电化学和生物信息科学的交叉融合和技术设计是快速即时体外诊断方法的发展趋势,对过敏体质及症状的及时发现和病情的早期控制和对人类生活质量的提高都有着重要的意义。
Abstract:
Drug allergies and its leading to anaphylactic shock are very serious problems for patients and clinicians. The incidence of allergies is unpredictable and life threatening. With the rapid development of new drugs and new chemical compounds, drug allergy problems seem to be more common and prominent. Current drugs allergy diagnostic methods are mainly in vivo skin prick test, intra-dermal techniques, and serum antigen-specific IgE test. These methods have certain restrictions and limited arranges, and even in vivo test(such as skin test)itself will have great risks. Therefore, study on diagnostic markers, establishment of in vitro diagnostic methods and predicting test systems are particularly important. Mast cells and basophils are core cells during allergic reaction development, which is characterized by cell activation/degranulation and then release the chemical mediators. This article described the cell activation mechanisms in drug allergies and anaphylactic shock, and also discussed cell-specific mediators as the diagnostic markers, including mast cell-specific proteases: tryptase, chymase and carboxypeptidase; the cell surface markers of basophile activation of CD63, CD203C, and basophile specific mediator basogranulin. This article also discussed other relevant mediators associated with allergies, such as histamine, dipeptidyl peptidaseⅠ,angiotensin converting enzyme and bradykinin, and suggested that the multiple bio-markers system should be fully developed for allergic or anaphylaxis diagnostics. The combined and cross-fields studies between the choices of fluorescent dyes, electrochemistry and biological information science will be the direction of development for the rapid, real-time in vitro diagnostic methods, which is of great significance to the timely and rapid discovery of disease and early control of disease progress, as well as to the improvement of human health and life quality.

参考文献/References:

[1]SIMONS F E R, EBISAWA M, SANCHEZ-BORGES M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines [J]. World Allergy Organization Journal, 2015, 8(1):1-16.
[2]桥本公二, 姚桢. DIHS的研究进展与诊断标准 [J]. 日本医学介绍, 2004, 25(2): 69-70.
[3]LEE J K, VADAS P. Anaphylaxis: mechanisms and management [J]. Clinical & Experimental Allergy, 2011, 41(7):923-938.
[4]PANESAR S S, JAVAD S, SILVA D D, et al. The epidemiology of anaphylaxis in Europe: a systematic review [J]. Allergy, 2013, 68(11):1353-1361.
[5]YU J E, LIN R Y. The epidemiology of anaphylaxis [J]. Clinical Reviews in Allergy & Immunology, 2015,49:1-9.
[6]TEJEDOR ALONSO M A, MORO M M, MUGICAGARCIA M V, et al. Incidence of anaphylaxis in the city of Alcorcon(Spain): a population-based study [J]. Clinical & Experimental Allergy, 2012, 42(4):578-589.
[7]DWORZYNSKI K, ARDERN-JONES M, et al. Diagnosis and management of drug allergy in adults, children and young people: summary of NICE guidance [J]. BMJ Clinical Research, 2014, 349(11): 4852.
[8]GIBBISON B, SHEIKH A, MCSHANE P, et al. Anaphylaxis admissions to UK critical care units between 2005 and 2009 [J]. Anaesthesia, 2012, 67(8):833-839.
[9]KILIMAJER J, ALAVA C, HERRERO T, et al. Epidemiology of drug hypersensitivity reactions in an allergy service [J]. Journal of Allergy & Clinical Immunology, 2011, 127(2):AB252.
[10]王倩. 输液室药物不良反应的临床观察和护理 [J]. 黑龙江医药, 2014, 27(5): 1211-1214.
[11]杨林, 刘光辉. 药物过敏发病机制及体内外检测 [J]. 中华临床免疫和变态反应杂志, 2012, 6(2):152-157.
[12]MICHALSKA-KRZANOWSKA G. Anaphylactic reactions during anaesthesia and the perioperative period [J]. Anaesthesiology Intensive Therapy, 2013, 44(2):104-111.
[13]IMANISHI H, KITAMURA A, MARUYAMA K, et al. Suspected recurrent anaphylaxis in different forms during general anesthesia [J]. Journal of Anesthesia, 2010, 24(1):143-145.
[14]CHONG Y Y, CABALLERO M R, LUKAWSKA J, et al. Anaphylaxis during general anaesthesia: one-year survey from a British allergy clinic [J]. Singapore Medical Journal, 2008, 49(6):483-487.
[15]GURRIERI C, WEINGARTEN T N, MARTIN D P, et al. Allergic reactions during anesthesia at a large United States referral center [J]. Anesthesia & Analgesia, 2011, 113(5):1202-1212.
[16]SAVIC L, WOOD P M, SAVIC S. Anaphylaxis associated with general anaesthesia: challenges and recent advances [J]. Trends in Anaesthesia & Critical Care, 2012, 2(6):258-263.
[17]VOEHRINGER D. Protective and pathological roles of mast cells and basophils [J]. Nature Reviews Immunology, 2013, 13(5):362-375.
[18]NGUYEN J, LUK K, VANG D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer [J]. Bja the British Journal of Anaesthesia, 2014, 113(7):4-13.
[19]MATITO A, ALVAREZ-TWOSE I, MORGADO J M, et al. Anaphylaxis as a clinical manifestation of clonal mast cell disorders [J]. Current Allergy and Asthma Reports, 2014, 14(8):1-10.
[20]ZHOU X, WHITE M, LAU L, et al. Anaphylaxis as a potential cause of death in heroin users [J]. Journal of Allergy & Clinical Immunology, 2012, 129(2):AB71.
[21]ZHOU X, BUCKLEY M G, LUCAS J, et al. Anaphylactic mechanisms in sudden unexpected infant death: Elevated concentrations of mast cell carboxypeptidase in the serum [J]. Journal of Allergy & Clinical Immunology, 2007, 119(1):148.
[22]EBO D G, FISHER M M, HAGENDORENS M M, et al. Anaphylaxis during anaesthesia: diagnostic approach [J]. Allergy, 2007, 62(5):471-487.
[23]TRAUTMANN A, SEIDL C, STOEVESANDT J, et al. General anaesthesia-induced anaphylaxis: impact of allergy testing on subsequent anaesthesia [J]. Clinical & Experimental Allergy, 2015, 46(1):125-132.
[24]PEDERSEN A F, GREEN S, ROSE M A. Failure to investigate anaesthetic anaphylaxis resulting in a preventable second anaphylactic reaction [J]. Anaesthesia & Intensive Care, 2012, 40(6):1053-1055.
[25]MAITRA S, SEN S, KUNDU S B, et al. Anaphylaxis from atracurium without skin manifestation [J]. Journal of Anaesthesiology Clinical Pharmacology, 2014, 30(1):104-105.
[26]SINGER E, ZODDA D. Allergy and anaphylaxis: principles of acute emergency management [J]. Emergency Medicine Practice, 2015, 17(8):1-24.
[27]KEMP S F, LOCKEY R F. Anaphylaxis: A review of causes and mechanisms [J]. Journal of Allergy & Clinical Immunology, 2002, 110(3):341-348.
[28]SIMONS F E R, FREW A J, ANSOTEGUI I J, et al. Risk assessment in anaphylaxis: current and future approaches [J]. Journal of Allergy & Clinical Immunology, 2007, 120(1):2-24.
[29]SCHLIEMANN S, SEYFARTH F, HIPLER U C, et al. Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1,092 dermatology patients [J]. Acta Dermato-Venereologica, 2012, 92(5): 484-489.
[30]SALACUNILL A, CARDONA V, ABRADORHORRILLO M, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients [J]. International Archives of Allergy & Immunology, 2013, 160(2):192-199.
[31]SRIVASTAVA S, HUISSOON A P, BARRETT V, et al. Systemic reactions and anaphylaxis with an acute serum tryptase ≥14 μg/L: retrospective characterisation of aetiology, severity and adherence to National Institute of Health and Care Excellence(NICE)guidelines for serial tryptase measurements and spec [J]. Journal of Clinical Pathology, 2014, 67(7):614-619.
[32]BUCKLEY M G, MCEUEN A R, WALLS A F. The detection of mast cell subpopulations in formalin-fixed human tissues using a new monoclonal antibody specific for chymase [J]. Journal of Pathology, 1999, 189(1):138-143.
[33]BUCKLEY M G, HE S, HE Y, et al. Carboxypeptidase as a marker of mast cell heterogeneity in human tissues [J]. Journal of Allergy & Clinical Immunology, 2006, 117(2):69.
[34]ZHOU X, BUCKLEY M G, LAU L C, et al. Mast cell carboxypeptidase as a new clinical marker for anaphylaxis [J]. Journal of Allergy & Clinical Immunology, 2006, 117(2):85.
[35]ZHOU X, WHITWORTH H S, E-KHEDR M, et al. Mast cell chymase: a useful serum marker in anaphylaxis [J]. Journal of Allergy & Clinical Immunology, 2011, 127(2):143.
[36]WALLS A F, ZHOU X. Mast cell carboxypeptidase as a marker for anaphylaxis and mastocytosis:US20110262931[P/OL].(2011-10-27)
[2012-09-04].http://www.freepatentsonline.com/y2011/0262931.html.
[37]GOLDSTEIN S M, KAEMPFER C E, PROUD D, et al. Detection and partial characterization of a human mast cell carboxypeptidase [J]. Journal of Immunology, 1987, 139(8):2724-2729.
[38]PAYNEA V, KAM P C A. Mast cell tryptase-role in the investigation of acute hypersensitivity reactions [J]. Current Anaesthesia & Critical Care, 2006, 17(17):29-35.
[39]BROWN T A, WHITWORTH H S, ZHOU X Y, et al. Mast cell carboxypeptidase as a confirmatory and predictive marker in allergic reactions to drugs [J]. Journal of Allergy & Clinical Immunology, 2011, 127(2):143.
[40]ZHOU X, UDDIN M, DJUKANOVIC R, et al. Dipeptidyl peptidase I(DPPI)as a modulator of elastase activity in human blood neutrophils [J]. Journal of Allergy & Clinical Immunology, 2009, 123(2):59.
[41]EL-FEKI G, ZHOU X, LAU L C, et al. Inhibitors of dipeptidyl peptidase I(DPPI)as mast cell stabilising agents: The contribution of DPPI in mast cell activation [J]. Journal of Allergy & Clinical Immunology, 2011, 127(2):131.
[42]WHITWORTH H S, LEACH S, ZHOU X, et al. Mast cell carboxypeptidase and angiotensin-converting enzyme(ACE)as serum markers of susceptibility to severe food allergic reactions [J]. Journal of Allergy & Clinical Immunology, 2010, 125(125):120.
[43]ZHOU X, EREN E, RAE W, et al. Bradykinin generation in acute allergic reactions and angioedema: roles of mast cell tryptase and chymase [J]. Journal of Allergy & Clinical Immunology, 2015, 135(2):64.
[44]RAAP U, WIECZOREK D, SCHENCK F, et al. The basophil activation test is a helpful diagnostic tool in anaphylaxis to sesame with false-negative specific IgE and negative skin test [J]. Allergy, 2011, 66(11):1497-1499.
[45]MCEUEN A R, BUCKLEY M G, COMPTON S J, et al. Development and characterization of a monoclonal antibody specific for human basophils and the identification of a unique secretory product of basophil activation [J]. Laboratory Investigation, 1999, 79(1):27-38.
[46]FAWZY A, NICHOLAS B L, LAU L C, et al. Preparation of a new basophil-specific monoclonal antibody: insights into the properties of basogranulin [J]. Journal of Allergy & Clinical Immunology, 2011, 127(2):56-66.
[47]CAUGHEY G H. Mast cell tryptases and chymases in inflammation and host defense [J]. Immunological Reviews, 2007, 217(1):141-154.
[48]JR M G D. Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils [J]. International Archives of Allergy & Immunology, 2012, 159(3):243-252.
[49]WOLTERS P J, PHAM C T, MUILENBURG D J, et al. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice [J]. Journal of Biological Chemistry, 2001, 276(21):18551-18556.
[50]LAROCHE D, CHOLLET-MARTIN S, LéTURGIE P, et al. Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to neuromuscular blocking agents [J]. Anesthesiology, 2011, 114(1):91-97.
[51]PERONI D G, SANSOTTA N, BERNARDINI R, et al. Muscle relaxants allergy [J]. International Journal of Immunopathology & Pharmacology, 2011, 24(24):35-46.
[52]YOON S Y, PARK S Y, KIM S, et al. Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: a prospective study with drug challenge [J]. Allergy, 2013, 68(7):938-944.
[53]柳丽, 周晓鹰. 肥大细胞在自身免疫性疾病中的研究进展[J]. 中国免疫学杂志, 2016, 32(9):1387-1390.
[54]周晓鹰, 储奕. 肥大细胞和类风湿关节炎[J]. 常州大学学报(自然科学版), 2016, 28(6):28-31.
[55]周晓鹰,唐颖娟,储奕. 肥大细胞以及和脑神经炎症相关的疾病[J]. 中国免疫学杂志, 2017, 33(5):228-235.
[56]LIU X,WANG J,ZHOU X. Serum based fluorescent assay for evaluating dipeptidyl peptidase I activity in collagen induced arthritis rat model[J]. Molecular and Cellular Probes, 2017, 32:5-12.
[57]王晶晶,蒋媛,周晓鹰, 等. 雷公藤多苷抑制二肽肽酶I活性及其调节机制的研究[J].中国免疫学杂志, 2017, 33(4):138-142.
[58]柳丽, 王晶晶, 周晓鹰,等.雷公藤多苷对胶原诱导关节炎大鼠滑膜肥大细胞浸润和活化的影响[J]. 常州大学学报(自然科学版), 2016, 28(5):82-86.

备注/Memo

备注/Memo:
收稿日期:2016-07-05。
基金项目:British Medical Research Council, UK(G0500729); 常州科技局国际交流研究基金项目(KYJ1520305); 常州大学高层次人才引进启动基金项目(ZMF14020066)。
作者简介:周晓鹰(1957—),女,英国籍,博士,英国南安普顿大学客座教授,博士生导师,主要从事免疫学和生物诊断技术研究。
更新日期/Last Update: 2017-06-05